To sign up for news alerts about Quintessence Biosciences, please fill out this form: http://eepurl.com/k4l49
Press Releases
15 June 2012
Quintessence Biosciences Meeting with Partners at 2012 BIO International Convention
31 May 2012
Quintessence Biosciences Presents on Phase I trial of Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Annual Meeting
19 April 2012
Quintessence Biosciences Selected for Buzz of BIO at 2012 BIO International Convention
12 April 2012
Quintessence Biosciences Announces Election of Walter Dewey to Board of Directors
30 March 2012
Quintessence Biosciences Presents Results for Combination Studies of Clinical Stage Ribonuclease QBI-139 at AACR Meeting
15 January 2010
Quintessence Biosciences to Present at Keystone Symposia’s RNA Silencing Conference
13 January 2010
Quintessence Biosciences Announces Expansion to The University of Texas M. D. Anderson Cancer Center of the Cancer Clinical Trial for QBI-139
6 January 2010
Quintessence Biosciences to Present at OneMedForum 2010
See an interview with Laura Strong, President and COO of Quintessence, at the OneMedForum 2010
13 November 2009
Quintessence Biosciences to Present QBI-139 Data at International Cancer Conference
3 September 2009
Quintessence Gets Support from the National Cancer Institute for Next Generation EVade™ RNases
26 March 2009
Patients Now Enrolling in Phase I Human Trial for Quintessence Biosciences Cancer Drug, QBI-139
5 December 2008
Quintessence Biosciences Cancer Drug, QBI-139, Clears FDA Review to Start Phase I Human Trial
23 October 2008
Quintessence Biosciences Present Efficacy Data for Next Generation EVade™ Ribonucleases at Cancer Meeting
6 October 2008
Federal Contract Awarded to Quintessence Biosciences Funding will support development of Next Generation EVade™ Ribonuclease Drug Candidates.
14 April 2008
Quintessence Biosciences, Inc. Presents IND-Enabling Toxicology Data at Cancer Meeting
5 February 2008
Althea Technologies Chosen by Quintessence Biosciences to Produce Lead Protein Oncology Drug
30 November 2007
Quintessence Biosciences, Inc. Announces Award of Two Federal Grants to Support Development of EVade™ Ribonuclease Products
22 October 2007
Quintessence Biosciences, Inc. Presents Additional Data on Lead Candidate
16 April 2007
Quintessence Biosciences, Inc. Presents Pre-clinical Toxicology Data at Cancer Meeting
8 February 2007
Quintessence Biosciences, Inc. Names Laura Strong, Ph.D. as President
9 November 2006
Quintessence Biosciences Confirms Selection of EVade™ Ribonuclease Cancer Treatment for Late Stage Pre-Clinical Studies
19 April 2005
Quintessence Biosciences Announces Start of Non-Clinical Studies on Lead Candidate QBI-139 at the 2005 Annual Meeting of the American Association of Cancer Research
Quintessence Biosciences, Inc. 